AAAF is dedicated to supporting research into Alopecia Areata. We have provided a range of grants and supported studies into both the medical and psychological impact of this condition.

Current Trials and Research

Clinical trials for new Alopecia Areata treatment options are currently running in Australia. AAAF will share updates as they become available. Be sure to register to sign up for newsletter updates.

Focus group seeking participants looking into the impact of Alopecia Areata on Quality of Life

If you’re over 18, live in or near Melbourne, and have a form of Alopecia Areata, we need your help!

AAAF is funding research into quality of life and mental health in people with Alopecia Areata. We’re seeking participants for a workshop to discuss exercise and physical activity, and how Alopecia Areata affects your life.
This workshop follows up a survey earlier this year, and is part of a long-term strategy to gain government support for people living with AA. Please show your support of research into this condition. 


The Cost to Government and Disutility of Alopecia Areata and an Investigator-Initiated, Placebo-controlled, Clinical Trial Investigating the Efficacy of Two Treatments for Alopecia Areata

This study aims to quantify the effectiveness of treatments for alopecia areata. We aim to use this data to support future applications for government contribution to treatments for Alopecia Areata, including listings on the PBS. There are 11 visits to the clinic over the course of the 2 stages. All study visits and medications are free of cost to participants.

If you are aged 18 -65 years, reside in Victoria and have moderate to severe alopecia areata you may be eligible for this trial.

To assess your eligibility, please complete the questionnaire in the link above. Your details will be forwarded to the Trials team and they will contact you shortly. Alternatively, please contact the trials unit at Sinclair Dermatology at


Associations between physical activity, quality of life (QoL) and mental health in patients with Alopecia Areata: The Physical Activity, quality of Life and Mental health (PALM) study. 

This survey should take around 25 minutes. It covers questions your socio-demographic data, physical activity participation, your state of mental health and about how much Alopecia Areata has affected your quality of life.

By participating in this survey, you are not only helping AAAF to improve our strategies, you also help future researchers looking to support people living with Alopecia Areata.



Currently running in Melbourne and Sydney is a clinical study for a treatment for complete or partial Eyebrow Hair Loss in Participants with Alopecia Areata, Alopecia Universalis and Alopecia Totalis. This trial is currently seeking participants. 


In 2017 a trial began on Oral Jak Inhibitors. The trial is ongoing, but recruitment is now closed. 


Medical Research


Systematic Review of the efficacy, safety and management considerations for tofacitinib – JAK Inhibitor use in Dermatology. 
Tofacitinib is one of the Janus Kinase (JAK) inhibitor drugs currently in trial as a treatment for Alopecia Areata. This study reviewed numerous papers about tofacitinib use to treat a range of dermatological conditions – Alopecia Areata, Atopic Dermatitis, Psorasis and Vitilago.

 Findings of most interest to individuals with Alopecia Areata include “Evidence for tofacitinibs’ efficacy in AA is stronger than for currently used systemics, which have not been subject to prospective trials. … Development of more “selective” JAK1/3 inhibitors, with theoretically less risk of hematopoietic toxicity, is presently being favored in clinical trials.” 

This poster was presented at the Australasian College of Dermatologists 2018 Annual Scientific Meeting. 


AAAF along with Sinclair Dermatology ran a 28 week study (starting in June 2015) on the treatment of Alopecia Areata with topical Janus kinase (JAK) Inhibitors.
Janus Kinase (JAK) inhibitors inhibit the activity of the JAK enzyme. The JAK enzymes are involved in signal transduction which plays a role in cytokine signalling. Cytokine signalling controls the growth of cells and the immune response. It is this immune response which causes alopecia areata. The purpose of this study is to demonstrate the efficacy of topical JAK inhibitors ruxolitinib ointment, tofacitinib ointment, versus clobetasol diproprionate ointment and placebo.


Four years ago, a team led by Professor Angela Christiano from the Columbia University Medical Centre discovered the genetic basis of alopecia areata, the most common auto-immune disease in humans. In this latest research, published in the scientific journal Nature Medicine, the same group had discovered the specific white blood cell, a type of t-cell, responsible for causing hair loss.

AAAF Funds Alopecia Areata research at Epworth Dermatology / University of Melbourne
AAAF has been successful in  securing the services of Jane Li a PhD student at the University of Melbourne, studying the subtypes of immune cells (known as T cells) in Alopecia Areata. T cells are a type of white blood cell involved in various immune responses in the body.  Much evidence exists to show AA is
a T cell mediated disorder.  Memory T cells are a subset of T cells that persist in the body and provide an immunological ‘memory’.  A new type of memory T cell known as resident memory T cells (TRM cells) has recently been described which reside in the skin and play an important part in skin immune function.

The overall objective of the research project is to determine the effects of corticosteroids on immune cells, known as T-cells, in the skin of alopecia areata patients.
Corticosteroids are the most common treatment for alopecia areata, but often cause debilitating side effects and has a 20% failure rate and significant side effects.  Understanding why the significant failure rate and relapse pattern are the main drivers for this research.


Psychological Research


AAAF engaged with RMIT University for study into the impact of physical activity on mental health and quality of life for people with Alopecia Areata. Ongoing study opportunities look toward analyzing physical and emotional barriers to physical activity experienced by people with Alopecia Areata, with a look toward identifying solutions to these barriers.

The current study is called “Associations between physical activity, quality of life (QoL) and mental health in patients with Alopecia Areata: The Physical Activity, quality of Life and Mental health (PALM) study.” by Jason Wong.


AAAF engaged the University of Victoria for study entitled: “Psychosocial Impact of living with a family member with Alopecia Areata” by Jennifer Davies


AAAF engaged the University of Victoria for two major pieces of psychological research.

1) The study is entitled “Alopecia and Acceptance: The Influence of Length in Time Since Diagnosis in Coping with Hair Loss Disorders.” by Ryan Veal

2) The study is entitled “Investigation the impact of Alopecia Areata on women’s self-esteem, mood states and coping”. by Jessica Martino


AAAF engaged the University of Victoria to do an exploratory study into  Coping and the Psychosocial Impact of Alopecia Areata in Young Australians: An Exploratory Study by Louise Borg.